Drugs or medicinal agents should only be used in pregnancy if there is proven benefit to the mother and no potential teratogenic risks. The present study was performed to evaluate the teratogenic effect of spiramycin in albino rats. The pregnant rats were divided into three groups, group (1) behaved as control received normal saline from 6^th to 15^h day of pregnancy. Group (2) received 150 mg/kg b.wt of spiramycin orally daily from 6^th to 15^th day of pregnancy. Group (3) received 300 mg/kg b.wt. of spiramycin orally daily from 6^th to 15^th day of pregnancy There is no death or abortions. Treated groups showed significant decrease in weight, length and retarded growth in fetuses. Fetal resorption significantly increased. The incidences of skeletal and visceral abnormalities were increased in treated groups.